8 results about "Busulfan" patented technology

The invention relates to the technical field of biomedicine, in particular to application of astaxanthin in preparation of a medicine for treating oligoasthenospermia caused by a chemotherapeutic drug busulfan. The astaxanthin disclosed by the invention is a natural product, is high in safety and small in toxic and side effects, has a good effect of treating oligospermia and asthenospermia, and provides a new natural medicine choice for clinically preventing and treating chemotherapy-related male infertility.

The invention relates to a construction method and application of an immune system sheep-derived mouse model, and the construction method comprises the following steps: 1) taking an adaptively cultured severe immunodeficiency mouse, and injecting busulfan to inhibit the hematopoiesis of the mouse; 2) injecting sheep spleen lymphocytes into the body of the pre-treated immunodeficient mouse in an orbital vein manner; 3) after the sheep cells are transplanted in the step 2), detecting the cell proportions of sheep CD45 +, CD4 + and CD8 + in the peripheral blood of the mouse every week so as to detect the sheep CD45 +, CD4 + and CD8 + in the peripheral blood and / or tissues, and determining that the immune system sheep mouse is successfully constructed if the sheep CD45 +, CD4 + and CD8 + can be continuously detected for 13 weeks; (4) injecting and infecting Brucella into the abdominal cavity of the mouse in the step (3) to obtain the Brucella infected sheep-derived mouse model.According to the method, sheep spleen lymphocytes are transplanted into the mouse body to construct the immune system sheep-derived mouse, and a more effective and more convenient animal model is provided for studying diseases such as Brucella taking sheep as a host.

The invention discloses a rapid breeding method for generating larimichthys crocea sperms based on spermatogonial stem cell transplantation. The rapid breeding method comprises the following steps: step S1, performing whole cryopreservation on larimichthys crocea testis; s2, separating the spermatogonial stem cells of the pseudosciaena crocea; s3, dyeing the spermatogonial stem cells of the pseudosciaena crocea; step S4, treatment of nibea albiflora receptors; and S5, transplanting the dyed donor larimichthys crocea spermatogonial stem cells into the nibea albiflora receptor testis. According to the method, when the nibea albiflora acceptor is treated, the traditional busulfan concentration of 40 mg / kg, twice injection and 35 DEG C high-temperature assistance is optimized into 60 mg / kg, single injection and 22 DEG C normal-temperature culture, optimal parameters induced by busulfan are screened out through experiments, the operation process is simplified under the action of ensuring that endogenous germ cells of the acceptor are reduced and immunological rejection is reduced, and the method is suitable for large-scale popularization and application. The harsh requirement of a high-temperature environment is avoided, and meanwhile the field planting efficiency of donor cells in receptors and the survival rate of the receptors are improved.

The invention provides a method for determining a Blonanserin related substance, and belongs to the technical field of pharmaceutical analys.The method comprises the steps that Blonanserin is taken to be prepared into a test solution, then a sodium dihydrogen phosphate buffer solution serves as a mobile phase A, a mixed solution of methyl alcohol and acetonitrile serves as a mobile phase B, high performance liquid chromatography detection is conducted through gradient elution, and the Blonanserin related substance is obtained. The method is used for detecting related substances in blonanserin. According to the present invention, with the specific high performance liquid chromatography condition, the variety and the content of the Blonanserin-related substance can be effectively determined, and the accuracy and the precision of the determination result are good.

The disclosure compositions and methods for non-genotoxic conditioning with an anti-CD45 antibody, anti-CD45 antibody drug conjugate, or anti-CD45 chimeric antigen receptor expressing T cell. The methods involve altering a CD45 polynucleotide sequence in an HSPC using a base editor to encode a CD45 polypeptide with reduced binding to the antibody. Embodiments of the disclosure also feature compositions and methods for treating diseases and conditions by non-genotoxic conditioning with an anti-CD45 antibody, anti-CD45 antibody drug conjugate, or anti-CD45 chimeric antigen receptor expressing T cell (CAR-T) prior to, simultaneously with, or after transplant of the based edited HSPC. The compositions and methods disclosed herein advantageously can reduce or eliminate the use of genotoxic agents such as busulfan, and provide edited HSPCs that are resistant to the disclosed anti-CD45 antibody, anti-CD45 antibody drug conjugate, and anti-CD45 chimeric antigen receptor expressing T cell.

This invention belongs to the field of animal model technology, specifically relating to a method for constructing an animal model of aplastic anemia and premature ovarian failure (POF) and its application in mesenchymal stem cell therapy. Busulfan and cyclophosphamide were administered intraperitoneally to the animals six times in the following order: first, busulfan was administered three times consecutively, followed by cyclophosphamide three times consecutively, thus establishing an animal model of the dual pathological state of aplastic anemia and POF. Furthermore, based on this animal model, a mesenchymal stem cell therapy based on disease stages was established, achieving significant recovery of ovarian function and providing a reliable technical foundation for clinical translational research on POF in adolescents.

The present disclosure relates to compositions and methods for non-genotoxic conditioning with anti-CD45 antibodies, anti-CD45 antibody drug conjugates, or anti-CD45 chimeric antigen receptor-expressing T cells. The methods include using a base editor to alter the CD45 polynucleotide sequence in HSPCs to encode a CD45 polypeptide with reduced binding to the antibody. Embodiments of the present disclosure also provide compositions and methods for treating diseases and conditions by non-genotoxic conditioning with anti-CD45 antibodies, anti-CD45 antibody drug conjugates, or anti-CD45 chimeric antigen receptor-expressing T cells (CAR-T) before, concurrently with, or after transplanting the base edited HSPCs. The compositions and methods disclosed herein can advantageously reduce or eliminate the use of genotoxic agents such as busulfan, and provide edited HSPCs that are resistant to the disclosed anti-CD45 antibodies, anti-CD45 antibody drug conjugates, and anti-CD45 chimeric antigen receptor-expressing T cells.

This invention discloses a busulfan nanomicelle, its lyophilized powder for injection, its preparation method, and its applications. The busulfan nanomicelle comprises busulfan, phospholipids, bile salts, stabilizers, and protectants. The lyophilized powder for injection is prepared by freeze-drying the busulfan nanomicelle prepared according to this invention. This invention aims to reduce the in vivo toxicity of busulfan, reduce the use of organic solvents, and improve the solubility and bioavailability of busulfan by preparing nanomicelles. This invention provides a novel formulation of busulfan, namely, a lyophilized micelle formulation, which improves drug stability, reduces drug toxicity, increases drug solubility, and enhances its in vivo bioavailability.